A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)

Astellas Pharma Inc691 enrolled

Overview

This study will examine the efficacy, safety and tolerability of different oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

691

Conditions

Irritable Bowel Syndrome

Interventions

YM060DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient meets Rome II criteria for IBS and the subgroup of diarrhea predominant IBS Exclusion Criteria: * Patient with severe cardiovascular disease, respiratory diseases, renal diseases, hepatic diseases, digestive tract diseases (excluding IBS), blood diseases, or neurological or psychiatric diseases * Patient reported having any Type 1 or Type 2 stool on the Bristol Stool Form Scale during the run-in period

Locations (45)

Unnamed facility

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.